Full-Year Earnings Presentation Materials for the Fiscal Year Ending September 2026 | Kringle Pharma,Inc. (4884) timely disclosure

Worth reading

40Recurring

0–100. This measures how worthwhile something is to read, not how good or bad the company is.

Direction

Mixed performance

Direction inferred from the company’s description.

Scale

370

¥ million (year-on-year increase in revenue)

Wording

Avoiding a definitive answer

How definitive the wording is.

Contents of this document

Results presentationFull year ended September 20267 items taken from the company’s own explanation

Financial Results Figures (The key points of this material are explained below)

Net Sales¥442 million+513.9%

Operating profit¥-813 million +10.6%operating loss

Ordinary income¥-810 million +11.4%ordinary loss

Net income¥-813 million +11.2%net loss

Selling, general and administrative expenses¥1,185 million

Full-year earnings forecast

Fiscal year ending September 2027

Net Sales

¥127 million

Cost of sales

¥0 million

Selling, General and Administrative Expenses

¥1,901 million

Research and Development Expenses

¥1,498 million

Operating loss

¥-1,773 million

Ordinary loss

¥-1,773 million

Net loss for the period

¥-1,775 million

What the company explained in this material

Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.

Drug substance supply and technology access fee income from ClarisListed as a reason for the increase in revenue
Contract upfront payment income from Maruishi PharmaceuticalListed as a reason for the increase in revenue
Decline in R&D expenditure64
Timing shift in expenses for developing a commercial formulation for vocal fold scarsListed as a reason for the decrease in expenses

Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.

Revenue from new partnerships and other arrangements may arise, but because this is uncertain at present, it has not been included in the revenue forecast for the fiscal year ending September 2027

New initiatives

Start of an additional Phase III trial in acute spinal cord injury
Establishment of a US subsidiary and US IND clearance
Exclusive marketing license agreement with Maruishi Pharmaceutical for a treatment for vocal fold scars
Advancement of preparations for a US Phase III trial in acute spinal cord injury
Preparation for establishing a manufacturing system for recombinant human HGF drug substance using a new manufacturing process
Funding through a private placement and stock acquisition rights

Key KPIsA metric the company considers important as a management benchmark.

Number of employees19 People
Improvement of 15 or more letters in visual acuity in LSCD (at week 20, CSB-001 treatment group)41 %
Improvement of 10 or more letters in visual acuity in LSCD (at week 20, CSB-001 treatment group)55 %
Durability of the CSB-001 effect (eyes with an improvement of 15 or more letters)58 %
Durability of the CSB-001 effect (eyes with an improvement of 10 or more letters)83 %

Financial targets

Actual results

Equity ratio57.1%

Market Size / Share

Acute Spinal Cord InjuryApproximately ¥12.0 billion
RegionJapan
Acute Spinal Cord InjuryApproximately ¥60 billion
RegionWorldwide
Vocal Fold ScarringApproximately ¥5.0 billion
RegionJapan
Vocal Fold ScarringApproximately ¥30 billion
RegionWorldwide
ALSApproximately ¥20.0 billion
RegionJapan
ALSApproximately ¥100 billion
RegionWorldwide

Number of employees

Number of Employees19 People

Contents of this document
Item	Details
Document type	Results presentation
Fiscal Period Covered	Full year ended September 2026
Net Sales	¥442 million (YoY +513.9%)
Operating profit	¥-813 million (operating loss) (YoY +10.6%)
Ordinary income	¥-810 million (ordinary loss) (YoY +11.4%)
Net income	¥-813 million (net loss) (YoY +11.2%)
Selling, general and administrative expenses	¥1,185 million
Full-year earnings forecast	Fiscal year ending September 2027 Net Sales ¥127 million / Cost of sales ¥0 million / Selling, General and Administrative Expenses ¥1,901 million / Research and Development Expenses ¥1,498 million / Operating loss ¥-1,773 million / Ordinary loss ¥-1,773 million / Net loss for the period ¥-1,775 million
Breakdown of Factors Affecting the Change	Factors Drug substance supply and technology access fee income from Claris / Amount Listed as a reason for the increase in revenue, Factors Contract upfront payment income from Maruishi Pharmaceutical / Amount Listed as a reason for the increase in revenue, Factors Decline in R&D expenditure / Amount 64, Factors Timing shift in expenses for developing a commercial formulation for vocal fold scars / Amount Listed as a reason for the decrease in expenses
Key KPIs	Indicator name Number of employees / Value 19 People / Year on year against the same period last year Not disclosed, Indicator name Improvement of 15 or more letters in visual acuity in LSCD (at week 20, CSB-001 treatment group) / Value 41 % / Year on year against the same period last year Not disclosed, Indicator name Improvement of 10 or more letters in visual acuity in LSCD (at week 20, CSB-001 treatment group) / Value 55 % / Year on year against the same period last year Not disclosed, Indicator name Durability of the CSB-001 effect (eyes with an improvement of 15 or more letters) / Value 58 % / Year on year against the same period last year Not disclosed, Indicator name Durability of the CSB-001 effect (eyes with an improvement of 10 or more letters) / Value 83 % / Year on year against the same period last year Not disclosed
Number of employees	Number of Employees 19 People / Change during the period Not disclosed / Hiring plan Not disclosed
Assumptions Underlying the Business Outlook	Revenue from new partnerships and other arrangements may arise, but because this is uncertain at present, it has not been included in the revenue forecast for the fiscal year ending September 2027
Financial targets	Target Not disclosed / Actual results Equity ratio 57.1%
Market Size / Share	Subject Acute Spinal Cord Injury / Region Japan / Market Size Approximately ¥12.0 billion, Subject Acute Spinal Cord Injury / Region Worldwide / Market Size Approximately ¥60 billion, Subject Vocal Fold Scarring / Region Japan / Market Size Approximately ¥5.0 billion, Subject Vocal Fold Scarring / Region Worldwide / Market Size Approximately ¥30 billion, Subject ALS / Region Japan / Market Size Approximately ¥20.0 billion, Subject ALS / Region Worldwide / Market Size Approximately ¥100 billion
New initiatives	Start of an additional Phase III trial in acute spinal cord injury, Establishment of a US subsidiary and US IND clearance, Exclusive marketing license agreement with Maruishi Pharmaceutical for a treatment for vocal fold scars, Advancement of preparations for a US Phase III trial in acute spinal cord injury, Preparation for establishing a manufacturing system for recombinant human HGF drug substance using a new manufacturing process, Funding through a private placement and stock acquisition rights

Items this document does not state (16)

Gross Profit MarginOperating profit marginResults for the three months of the current quarterProgress against full-year forecastSelf-assessment against the planSegment resultsUnit price and quantity metricsNumber of stores and locationsRisk amount incorporated into the outlookMedium-term management plan targetsAnnual DividendPayout ratioAcquisition of treasury sharesCapital expendituresOrders received and order backlogKey points of the Q&A

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The increase in revenue for the fiscal year ended September 2026 was attributable to drug substance supply and technology access fee income from Claris, as well as contract upfront payment income from Maruishi Pharmaceutical. The reduction in losses was due to higher revenue, lower research and development expenses and other factors. The increase in losses forecast for the fiscal year ending September 2027 is due to higher research and development expenses for an additional domestic Phase III trial in acute spinal cord injury, preparations for a Phase III trial in the United States, and preparations for manufacturing a commercial formulation for vocal fold scars.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.

Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.

Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.